Aktienanalyse zu Journey Medical Corp (DERM)DERMJourney Medical Corp

Journey Medical Corporation is a commercial-stage pharmaceutical company. The Company is focused on selling and marketing of the United States Food and Drug Administration (FDA) approved prescription pharmaceutical products for the treatment of dermatological conditions. Its portfolio includes eight FDA-approved prescription drugs for dermatological conditions that are marketed in the United States. Its marketed products, which have been approved FDA for sale in the United States, include Qbrexza, Accutane, Amzeeq, Zilxi, Exelderm Cream and Solution, Targadox, and Luxamend. Qbrexza is a medicated cloth towelette for the treatment of primary axillary hyperhidrosis. Accutane is an oral isotretinoin drug for the treatment of severe recalcitrant nodular acne. Targadox is an oral doxycycline drug for adjunctive therapy for severe acne. Luxamend is a water-based emulsion formulated to provide moist healing environment. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).

Journey Medical Corp (DERM) is a good buy right now due to its recent strong earnings growth, with a reported revenue of $18.5 million in Q2 2026, a 23% increase year-over-year, and a significant reduction in net loss to $300,000, or $0.01 per share. The current price of $4.79 is well below the analyst price target of $15, indicating substantial upside potential. However, the RSI is at 33.735, suggesting that the stock is currently oversold, which could present a buying opportunity. The main risk is the forward P/E ratio of 20.70, indicating that the stock may be overvalued if earnings do not improve as expected.

8 analysts cover DERM: 7 rate it Buy, 0 Hold and 1 Sell. The average price target is 14.00.